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MARC Project 5:
MOLECULAR
EPIDEMIOLOGY OF
ALCOHOLISM AND
COMORBID
DISORDERS

ABSTRACT: This new MARC research project, project
5, seeks to build upon gene-discovery projects such as
COGA (Collaborative Study on the Genetics of Alcoholism:
PIs Begleiter and Reich) and similar projects (e.g. PIs Hill,
Kendler) which are studying treatment-ascertained
alcoholics and their relatives, and the MARC-affiliated
Alcohol-QTL IRPG consortium (PIs Heath, Martin,
Madden, Todd), which is studying community-ascertained
alcoholics and heavy smokers and their adult relatives, by
incorporating a molecular genetic component into 4 mature,
prospective longitudinal studies (PIs Chassin, Cooper,
Heath, Sher) spanning the age-range from early adolescence
into young adulthood, with 3-7 waves of prospective
assessment. In addition to collecting DNA from the target

samples (years 1-3), this research project will combine
secondary data-analysis and genotyping, proceeding in 4
stages: (i) longitudinal and other phenotypic analyses to
establish consistent phenotype definition across informative
data-sets (not all data-sets will be informative for all
phenotypes of interest) (years 1-3); (ii) behavioral genetic
analyses using existing twin data sets (MOAFTS, the former
MARC Project 1, or other U.S. and Australian data-sets to
which we have access through the MARC) to confirm
heritability of phenotypes defined at stage (i), and where
possible determine whether that phenotypic operationalization is optimal for understanding genetic effects (which
may not be the case if the structures of genetic and
environmental influences are very different) (years 1-3); (iii)
genotyping for a limited number of candidate genes (years
3-5); and (iv) genetic association analysis (years 4-5). This

carefully staged approach is necessary to minimize the
dangers of multiple testing when combining candidate gene
data and rich longitudinal data sets. For the same reason,
we focus on a limited number of candidate phenotypes
where prospective data are expected to be informative for
understanding the etiology of alcoholism, as justified under
Background and Preliminary studies.
Selection of
candidate phenotypes and candidate genes is guided by the
MARC focus on the roles of overlapping mechanisms of
behavioral under control, negative affect regulation and
pharmacologic vulnerability in the etiology of alcohol use
disorders (AUDs), emphasizing AUD phenotypes associated
with (a) externalizing symptoms, (b) tolerance and
quantitative consumption indices, (c) cognitive aspects of
alcohol use (expectancies), (d) co-occurrence with tobacco
dependence, and (e) negative affect (depression, suicidality).

1. SPECIFIC AIMS
Project Goals
1.1. To obtain blood samples for DNA extraction, from
participants in 4 prospective longitudinal studies (PI-s
Chassin, Cooper, Heath, Sher).
1.2. To derive phenotypes of alcohol involvement (use and
problems) and co-occurring features based on longitudinal
course, that can be operationalized across two or more
data-sets, focused on four domains: (i) externalizing
symptoms; (ii) consumption, as well as cognitive aspects of
alcohol use (expectancies); (iii) co-occurrence with tobacco
dependence; (iv) co-occurrence with early trauma and
depression, from the databases of these 4 studies. Two
approaches will be emphasized for phenotype identification
– developmental (e.g. using mixture modeling to identify

trajectories through time); and state/trait modeling (e.g.
modeling chronicity of effects).
1.3. To conduct secondary analyses of existing twin and
children-of-twins data sets to confirm heritability of the
variables thus defined, excluding non-genetic phenotypes
from further analysis, and further refining phenotypes
where necessary.
1.4. Following these two stages of secondary data-analysis,
to test for candidate gene effects on these phenotypes
(however, choice of candidate gene is expected to need
revision in the light of emerging findings from ongoing
gene-discovery efforts, including MARC-affiliated projects,
by the time the genotyping phase of the project begins):
(i) AUDs and externalizing symptoms (DRD4, DRD5,
SLC6A3 (DAT1 in old notation));

(ii) AUDs, alcohol consumption and alcohol expectancies
(ALDH2 promoter polymorphism, ADH1B (ADH2 in old
notation), ADH1C (ADH3 in old notation);
(iii) AUDs and tobacco consumption (CHRNA4, CHRNA7,
CHRNB2);
(iv) AUDs and early trauma and other high-risk
environmental exposures associated with parental
alcoholism (CRF, NPY, SLC6A4 (HTT in old notation)).
1.5. Through the availability of DNA from the participants
in these longitudinal studies, to encourage future
coordinated genotyping efforts by the principal
investigators of the original studies, beyond the 5-year
funding period of this center project, to take full advantage
of the information about alcoholism etiology that has been
gathered in these studies.

PRELIMINARY RESULTS
Current progress for this study has occurred on two fronts.
First, several meetings have been held to discuss how to join data
sets together to develop phenotypes for analysis. The consensus
is that phenotypes will be initially developed in the two
University of Missouri data sets then tested for heritability in the
MOAFTS (Missouri Adolescent Female Twin Study) data set.
Common items and constructs are being developed. Second, a
test of how to approach subjects for blood collection is underway
in the Sher et al. study. Initially, 89 individuals have been
contacted to assess interest in the study. To date, 85 have agreed
to participate (a 95.5% initial cooperation rate). Soon, materials
for blood collection will be mailed to potential participants. The
participants will go to local clinics or laboratories for blood
drawing and samples will be express shipped to the laboratory at
Washington University.

